Endogena is a biotech company that develops endogenous regenerative medicines to repair and regenerate tissues and organs. Endogena's approach has the potential of a paradigm shift to treat degenerative conditions related to ageing and genetic disorders. The company implements innovation in the field of regenerative medicine. Their science combines the latest developments in stem cell biology, AI, and expertise in small-molecule drug design to develop breakthrough treatments for degenerative diseases.
DiA Imaging Analysis provides advanced AI-based ultrasound analysis smarter and accessible. It solves the two main challenges clinicians face when using ultrasound: acquiring the right image and automatically analyzing it, to find clinical abnormalities that today they are struggling to find visually. DiA's automated tools can be easily be added to any ultrasound device or healthcare IT system, just like an App. The company holds FDA/CE Clearances for its cardiac toolbox, generating revenues and having thousands of users around the world.
Acepodia is a clinical-stage biotechnology business that is using its proprietary Antibody-Cell Conjugation (ACC) platform technology to produce first-in-class cell treatments to solve gaps in cancer care. Acepodia employs this live-cell compatible chemistry to attach tumor-targeting antibodies directly to a variety of immune cell receptors, enhancing the lock between immune and cancer cells and generating highly specific, potent cell therapies without the need for genetic engineering. Acepodia is committed to immunotherapeutic strategies against oncology – expanding our research, clinical development, and manufacturing capabilities. Acepodia currently has a broad pipeline portfolio, each targeting a different type of cancer.
Endogena is a biotech company that develops endogenous regenerative medicines to repair and regenerate tissues and organs. Endogena's approach has the potential of a paradigm shift to treat degenerative conditions related to ageing and genetic disorders. The company implements innovation in the field of regenerative medicine. Their science combines the latest developments in stem cell biology, AI, and expertise in small-molecule drug design to develop breakthrough treatments for degenerative diseases.
Aegle Therapeutics is a privately-held biotechnology company developing a first in class therapy using extracellular vesicles, including exosomes, secreted by allogeneic bone marrow-derived mesenchymal stem cells. Aegle's platform technology is initially being developed to treat dystrophic epidermolysis bullosa, a rare pediatric skin blistering disorder. Aegle's IND for DEB has been cleared by the FDA and the company expects to enter the clinic by the 2H of 2020. Its proprietary platform isolation technology is cell-free and has the potential to demonstrate a safer, lower-cost means of harnessing the regenerative healing power of stem cells without using the cells. Aegle believes its EV therapy has the potential for functional regeneration and organization of complex tissue structures that can enhance healing, reduce scarring, minimize contraction, and improve overall cosmesis. The company was founded in 2013 and is based in Miami, Florida.
InformAI builds business analytics and artificial intelligence-based solutions for industry-leading healthcare organizations, medical device companies and imaging/PACS companies to improve mission outcome and operational improvement. The company provides computer consulting, artificial intelligence-based software solutions for image classification, natural language processing for operational processes, and prediction algorithms for mission-critical applications.InformAI develops AI-enabled healthcare diagnostic-assist tools and patient outcome predictors for leading healthcare systems and national physician groups. The company's AI software enables faster patient diagnoses at the point of care and improved patient outcome risk analysis.
Tara Biosystems provides predictive, in vitro human cardiac tissue models for use in drug discovery, safety assessment and translational medicine. Tara Biosystems offers a high-fidelity solution that is based on human stem cell-derived cardiac tissue matured to physiologically relevant adult-like levels and provides direct measures of cardiac functionality, including contractile force. The company is dedicated to pioneering predictive cardiac tissue models that enable the faster, safer, and more reliable development of new medicines.
1World Online is a A.I.-powered platform that unifies the values of data and advertising into an all-in-one engagement driven model. With 1World Online, websites will enjoy higher metrics of engagement, business teams will be able to better understand, profile, and monetize the audience, editors and journalists gain access to timely news content and can better target stories, and improve reader relationships. The company was founded in 2011 and is headquartered in California and Switzerland.
Aegle Therapeutics is a privately-held biotechnology company developing a first in class therapy using extracellular vesicles, including exosomes, secreted by allogeneic bone marrow-derived mesenchymal stem cells. Aegle's platform technology is initially being developed to treat dystrophic epidermolysis bullosa, a rare pediatric skin blistering disorder. Aegle's IND for DEB has been cleared by the FDA and the company expects to enter the clinic by the 2H of 2020. Its proprietary platform isolation technology is cell-free and has the potential to demonstrate a safer, lower-cost means of harnessing the regenerative healing power of stem cells without using the cells. Aegle believes its EV therapy has the potential for functional regeneration and organization of complex tissue structures that can enhance healing, reduce scarring, minimize contraction, and improve overall cosmesis. The company was founded in 2013 and is based in Miami, Florida.
Actuate Therapeutics provides advanced research for the treatment of high-impact cancers and neurodegenerative diseases. It is a private biopharmaceutical company focused on the development of compounds for use in the treatment of cancer and inflammatory diseases leading to fibrosis and neurodegeneration. The company aims to discover, develop, and commercialize new agents that target GSK-3β. Actuate Therapeutics is currently advancing its lead molecule, 9-ING-41, toward the clinic in 2017. Ongoing research has demonstrated significant anti-tumor activity in many in vivo models of difficult-to-treat cancers, including cancers of the brain, pancreas, lung, and breast. We are unaware of any published research demonstrating the kind of efficacy in treatment-resistant glioblastoma that we have been able to achieve with 9-ING-41. Importantly, the toxicity and pharmacokinetic profiles of the drug candidate are quite attractive.
BioEclipse Therapeutics is a clinical-stage oncology company that develops immuno-oncology therapeutics using its proprietary technology. Its mission is to improve clinical outcomes and the quality of life for all cancer patients and to be at the forefront of turning cancer into a curable disease. The company has harnessed a refined understanding of the human immune system, gaining insights into the reasons the body’s defense system so often turns a blind eye to the presence of cancerous cells and tumors. In response, BioEclipse Therapeutics pairs activated immune cells with an adapted oncolytic virus that selectively infects and kills malignant cells.
Actuate Therapeutics provides advanced research for the treatment of high-impact cancers and neurodegenerative diseases. It is a private biopharmaceutical company focused on the development of compounds for use in the treatment of cancer and inflammatory diseases leading to fibrosis and neurodegeneration. The company aims to discover, develop, and commercialize new agents that target GSK-3β. Actuate Therapeutics is currently advancing its lead molecule, 9-ING-41, toward the clinic in 2017. Ongoing research has demonstrated significant anti-tumor activity in many in vivo models of difficult-to-treat cancers, including cancers of the brain, pancreas, lung, and breast. We are unaware of any published research demonstrating the kind of efficacy in treatment-resistant glioblastoma that we have been able to achieve with 9-ING-41. Importantly, the toxicity and pharmacokinetic profiles of the drug candidate are quite attractive.
Immusoft is a biotechnology company that is commercializing technology to program the human immune system by modifying the DNA in immune cells. The core components of Immusoft’s Immune System Programming (ISP) technology was developed in the Baltimore Lab at the California Institute of Technology (Caltech) and exclusively licensed by Immusoft. The technology instructs a patient’s cells to produce gene-encoded medicines (biologics). Cells that are reprogrammed using ISP become miniature drug factories that are expected to survive in patients for many years. It was founded in 2009 and is headquartered in Seattle, Washington.
Savonix provides a valid and reliable measurement of cognitive function mapped to real world outcomes in domains like cognitive flexibility and on road performance in aging populations. Their customers include doctors, researchers, Fortune 50 insurance, and governments. Their platform provides users with easy to use and accessible tests of their brain function in multiple domains from memory to implicit learning that they can complete on a smartphone or tablet – guided and reported on by a virtual clinician. This information can in turn be used to understand risk for dementia and other brain disorders, as well as drive precision medicine in treatment planning and diagnosis. Unique to Savonix is their 3D game platform for testing that drives meta-data which has already resulted in the ability to report on the novel cognitive domain of Implicit Learning without adding a test but deriving it from passive in app performance in gold standard measures. Savonix is the only widely available mobile-ready digital cognitive test for early detection of cognitive change that is backed by decades of research into cognitive testing. They didn’t invent the wheel, they made it affordable, accessible, actionable and scalable.
Touchence is a technology company developing innovative tactile sensor solutions that offers a one-stop service for businesses.
DiA Imaging Analysis provides advanced AI-based ultrasound analysis smarter and accessible. It solves the two main challenges clinicians face when using ultrasound: acquiring the right image and automatically analyzing it, to find clinical abnormalities that today they are struggling to find visually. DiA's automated tools can be easily be added to any ultrasound device or healthcare IT system, just like an App. The company holds FDA/CE Clearances for its cardiac toolbox, generating revenues and having thousands of users around the world.
ORIG3N is a biotechnology company developing breakthrough treatments for rare genetically inherited diseases with targets in heart, liver, and neurodegenerative indications. It was founded in 2014 and is based in Boston, Massachusetts.
ORIG3N is a biotechnology company developing breakthrough treatments for rare genetically inherited diseases with targets in heart, liver, and neurodegenerative indications. It was founded in 2014 and is based in Boston, Massachusetts.
ORIG3N is a biotechnology company developing breakthrough treatments for rare genetically inherited diseases with targets in heart, liver, and neurodegenerative indications. It was founded in 2014 and is based in Boston, Massachusetts.
1World Online is a A.I.-powered platform that unifies the values of data and advertising into an all-in-one engagement driven model. With 1World Online, websites will enjoy higher metrics of engagement, business teams will be able to better understand, profile, and monetize the audience, editors and journalists gain access to timely news content and can better target stories, and improve reader relationships. The company was founded in 2011 and is headquartered in California and Switzerland.
The experience is centered on the personalized TV guide. On MeeVee, you select from a list of favorite actors, genres, subjects, or enter keyword interests (e.g. "golf"). The guide then finds upcoming programming based on those interests. It's a saved search so it'll keep looking for those programs for you until you remove the interests. If you love "Jennifer Aniston", you can add her as a favorite actress or keyword and, until you delete her, all shows or movies on TV with Jennifer Aniston showing through your cable or satellite provider will populate your guide. If you are willing to invest the time, you can build a totally customized TV guide and ditch the universal grid completely. It's an easy-to-use application and it's a nice model for building a personalized web experience. The TV listings widget (called "MeeVee Guide") they've built shows your personal guide to visitors of your pages on other sites. You can add to a page by pasting a snippet of code to it.
The experience is centered on the personalized TV guide. On MeeVee, you select from a list of favorite actors, genres, subjects, or enter keyword interests (e.g. "golf"). The guide then finds upcoming programming based on those interests. It's a saved search so it'll keep looking for those programs for you until you remove the interests. If you love "Jennifer Aniston", you can add her as a favorite actress or keyword and, until you delete her, all shows or movies on TV with Jennifer Aniston showing through your cable or satellite provider will populate your guide. If you are willing to invest the time, you can build a totally customized TV guide and ditch the universal grid completely. It's an easy-to-use application and it's a nice model for building a personalized web experience. The TV listings widget (called "MeeVee Guide") they've built shows your personal guide to visitors of your pages on other sites. You can add to a page by pasting a snippet of code to it.
The experience is centered on the personalized TV guide. On MeeVee, you select from a list of favorite actors, genres, subjects, or enter keyword interests (e.g. "golf"). The guide then finds upcoming programming based on those interests. It's a saved search so it'll keep looking for those programs for you until you remove the interests. If you love "Jennifer Aniston", you can add her as a favorite actress or keyword and, until you delete her, all shows or movies on TV with Jennifer Aniston showing through your cable or satellite provider will populate your guide. If you are willing to invest the time, you can build a totally customized TV guide and ditch the universal grid completely. It's an easy-to-use application and it's a nice model for building a personalized web experience. The TV listings widget (called "MeeVee Guide") they've built shows your personal guide to visitors of your pages on other sites. You can add to a page by pasting a snippet of code to it.
Fortinet is a provider of network security appliances that delivers a high level of network, content, and application security for enterprises of all sizes, managed service providers, and telecommunications carriers while reducing the total cost of ownership and providing a flexible, scalable path for expansion.
Fortinet is a provider of network security appliances that delivers a high level of network, content, and application security for enterprises of all sizes, managed service providers, and telecommunications carriers while reducing the total cost of ownership and providing a flexible, scalable path for expansion.
As of June 11, 2007, BroadWare Technologies, Inc. was acquired by Cisco Systems, Inc. BroadWare Technologies, Inc., a network video systems company, engages in the development and delivery of platforms and end-to-end browser-based solutions for collecting, recording, routing, and managing live and archived surveillance video. It offers Media Platform, a suite of server-based technologies for management, distribution, and storage of video surveillance data in a network environment; and Application Server, which enables users to determine levels of authority for viewing cameras, creating or viewing archives, and controlling movable cameras. The company offers Command Server, a digital matrix switch that allows each operator and intelligent application to control the video being displayed on various monitors; and Media Server that enables distribution, archiving, and management of video feeds. In addition, BroadWare Technologies provides specialty professional services, education and training, and support services. The company provides its products for use in applications, such as military bases, unmanned vehicles, embassies, corrections, border control, perimeter montoring, law enforcement, airports and seaports, homeland security, traffic montoring, and public infrastructure montoring, as well as corporate security, retail, public transit systems, gaming, health care, colleges and universities monitoring, petro-chemical, utlitites, and financial services. It serves airports and seaports, transportation systems, and various federal agencies and military branches. The company, formerly known as Graham Technology Solutions, was founded in 1995 and is headquartered in Santa Clara, California.
Fortinet is a provider of network security appliances that delivers a high level of network, content, and application security for enterprises of all sizes, managed service providers, and telecommunications carriers while reducing the total cost of ownership and providing a flexible, scalable path for expansion.
Oplus Technologies Ltd., a fabless semiconductor company, designs, develops, and markets integrated circuit display processors and software solutions for the digital display market. It offers multimedia display and video processors for flat panel plasma and LCD displays, TVs, projection systems, LCD monitors, and digital display applications. The company also provides system-on-chip solutions. It serves consumer electronics companies and display device manufacturers in Israel and internationally. Oplus Technologies Ltd. was founded in 1993 and is headquartered in Yokneam, Israel.
SourceGate Systems, developers of a managed service which enables ISPs to create new advertising-based revenue streams.
Intraspect Software provides inter-enterprise solutions for collaborative business processes. The company offers solutions for portal collaboration that enables its portal users to create shared communities and collaborate on areas relevant to the organization which includes strategic accounts, products, and business processes. It offers Intraspect 5.5 which provides architectural enhancements for inter-enterprise deployments and C-mail Services that allows its users to interact with Intraspect solutions using a communication method in business. Intraspect Software is a U.S.-based company that was founded in 1995 and it was acquired in 2003 by Vignette.